DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Pathophysiological Implications of the Incretin Hormones in Maturity Onset of Diabetes of the Young (MODY)

Information source: University Hospital, Gentofte, Copenhagen
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Maturity-onset Diabetes of the Young

Intervention: Oral Glucose Tolerance Test (OGTT) (Other); iso glycaemic intravenous (iv) glucose infusion (IIGI) (Other); Meal test (Dietary Supplement); Sitagliptin (Other); Incretin effect on sulphonyl urea treatment (Other)

Phase: N/A

Status: Completed

Sponsored by: University Hospital, Gentofte, Copenhagen

Official(s) and/or principal investigator(s):
Signe H Østoft, MD, phd stud, Principal Investigator, Affiliation: Diabetes Research Division, University Hospital Gentofte, Denmark

Summary

The purpose of this study is to describe the incretin effect and postprandial incretin response in patients with MODY2 and MODY3 and a group of matched healthy subjects. In sulphonyl urea treated subjects the purpose is also to compare the incretin effect with and without treatment. In healthy subjects the purpose is also to investigate the incretin effect under increased levels of endogen incretin hormones.

Clinical Details

Official title: Postprandial Secretion of of Incretin Hormones and Incretin Effect in Patients With Maturity-onset Diabetes of the Young (MODY)

Study design: Observational Model: Cohort

Primary outcome: Incretin effect

Secondary outcome:

Plasma GLP1 response

Plasma GIP response

Plasma glucagon response

Detailed description: Comparison of of insulin secretion (AUC) during the experimental days. Furthermore a comparison of GIP, GLP1 and glucagon responses as well as plasma glucose levels.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Caucasians above 18 years

- BMI > 19 kg/m2

- Negative pancreatic beta cell- and glutamate decarboxylase-65(GAD65)-

autoantibodies

- Normal haemoglobin

- Normal bloodpressure

- Informed concent

Exclusion Criteria:

- Known liver disease or affected liver enzymes (ALAT/ASAT >2 x upper normal limit)

- Nephropathy (see creatinine> 130 μM and / or albuminuria)

- Treatment with medications that cannot be discontinued for 12 hours

- Any condition that the investigators feel would interfere with trial participation

- Pregnancy or lactation

Locations and Contacts

Diabetes Research Division, Gentofte University Hospital, Niels Andersens vej 65, opgang 40, 2., Hellerup 2900, Denmark
Additional Information

Starting date: January 2011
Last updated: January 14, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017